SCHEMBL2825547

SCHEMBL2825547

COc1cccc(C=Cc2nc3ccccn3c(=O)c2-c2ccncc2)c1OC1CCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 3/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TRPM8 Q7Z2W7 2/20 0.34
PDE4A P27815 3/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
S1PR1 P21453 1/20 0.33
S1PR3 Q99500 1/20 0.33
PDE4D Q08499 2/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
MAPK14 Q16539 1/20 0.33
KMT2A Q03164 1/20 0.33
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
BACE1 P56817 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2825545 1.00 LMNA (0.38) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL2819041 0.94 LMNA (0.39) LMNASMN1; SMN2L3MBTL1MAPTTRPM8
SCHEMBL2819037 0.94 LMNA (0.39) LMNASMN1; SMN2L3MBTL1MAPTTRPM8
SCHEMBL2820864 0.90 NFE2L2 (0.40) LMNASMN1; SMN2L3MBTL1MAPTTRPM8
SCHEMBL13021125 0.90 CYP1A1 (0.39) LMNASMN1; SMN2L3MBTL1MAPTTRPM8
SCHEMBL2823170 0.90 LMNA (0.36) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL2818912 0.89 SMN1; SMN2 (0.36) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL2821318 0.89 KCNK3 (0.37) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL2821317 0.89 KCNK3 (0.37) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL2821911 0.89 PDE4A (0.40) LMNASMN1; SMN2L3MBTL1MAPTTRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349846-B2 Fused pyrimidine derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2013-01-08 US claimed
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-11-18 US claimed
US-8349846-B2 Fused pyrimidine derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2013-01-08 US disclosed
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators TRPV3, TRPV1, TRPV5 LMNA 2123/4885SMN1; SMN2 4045/4885L3MBTL1 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.